KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

AbbVie (ABBV) EBIT Margin (2016 - 2026)

AbbVie has reported EBIT Margin over the past 14 years, most recently at 27.34% for Q4 2025.

  • Quarterly EBIT Margin rose 3721.0% to 27.34% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 24.65% through Dec 2025, up 843.0% year-over-year, with the annual reading at 24.65% for FY2025, 843.0% up from the prior year.
  • EBIT Margin was 27.34% for Q4 2025 at AbbVie, up from 12.07% in the prior quarter.
  • Over five years, EBIT Margin peaked at 36.39% in Q4 2022 and troughed at 9.87% in Q4 2024.
  • The 5-year median for EBIT Margin is 27.81% (2024), against an average of 25.62%.
  • Year-over-year, EBIT Margin plummeted -3221bps in 2024 and then skyrocketed 3721bps in 2025.
  • A 5-year view of EBIT Margin shows it stood at 34.09% in 2021, then increased by 7bps to 36.39% in 2022, then tumbled by -39bps to 22.34% in 2023, then crashed by -144bps to 9.87% in 2024, then surged by 377bps to 27.34% in 2025.
  • Per Business Quant, the three most recent readings for ABBV's EBIT Margin are 27.34% (Q4 2025), 12.07% (Q3 2025), and 31.73% (Q2 2025).